Post-exposure prophylaxis for meningococcal disease

01Role and principlesWho benefits and the main preventive aims.

Meningococci commonly colonise the nasopharynx without disease. Invasive infection occurs in a small minority, but household and direct secretion exposure raises short-term risk because contacts can share the outbreak strain and susceptibility. Chemoprophylaxis eradicates carriage rapidly, reducing secondary cases; it does not provide lasting immunity.

Risk assessment depends on closeness and secretion exposure, not fear or room-sharing alone. Health protection defines the infectious interval, eligible contacts, antibiotic and any MenACWY or MenB vaccination. The index patient may also need carriage eradication if the therapeutic antibiotic did not reliably clear the nasopharynx.

Key points

Notify suspected meningococcal disease immediately; the health-protection team, not an informal contact list, defines who receives prophylaxis.
Close contacts usually include household-like exposure, intimate kissing and direct unprotected contact with respiratory secretions around the infectious period.
Healthcare staff need prophylaxis only after direct exposure to large-droplet secretions without appropriate protection, such as airway resuscitation.
Give prophylaxis as soon as possible, ideally within 24 hours of identifying the index case, while later presentation still requires health-protection advice.
Ciprofloxacin 500 mg orally once is a common adult first option when there is no resistance alert or contraindication.
Ceftriaxone 250 mg intramuscularly once is an effective pregnancy-compatible alternative selected by health protection.
Rifampicin 600 mg orally twice daily for 2 days is an alternative but has major interactions, stains secretions and can select resistance.
Chemoprophylaxis does not treat symptomatic invasive disease and does not replace serogroup-specific vaccination when health protection recommends it.

02Assessment and patient selectionRisk features, eligibility and important cautions.

Household-like contact

Sleeping, living or sharing intimate daily exposure with the index case during the infectious period generally meets close-contact criteria.

Direct secretion exposureRed flag

Unprotected mouth-to-mouth resuscitation, intubation splash or intimate kissing creates a carriage exposure that health protection evaluates promptly.

Casual proximity

Classroom, office, waiting-room or ward presence without direct secretion exposure usually does not justify prophylaxis.

Symptomatic contactRed flag

Fever, headache, meningism, severe limb pain or rash represents possible disease and requires emergency clinical treatment.

Red flags requiring action

Any invasive symptom in a contact triggers emergency treatment, not a chemoprophylaxis appointment.
Household, intimate kissing and direct unprotected airway-secretion exposure are higher-risk contacts requiring rapid health-protection assessment.
Routine proximity at work, school or hospital does not automatically meet contact criteria and indiscriminate antibiotics cause harm.
Pregnancy, severe allergy, fluoroquinolone contraindication or resistant strain changes the prophylactic agent but not the urgency.

03Baseline assessmentMeasurements that guide the plan and track progress.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Clinical symptom screenFirst step
Why
Separate asymptomatic contacts from people who may already have invasive disease.
Interpretation and limitations
Any systemic or neurological symptom redirects immediately to emergency assessment; prophylaxis cannot be used as a diagnostic trial.
02
Health-protection exposure assessment
Why
Define infectious dates, intensity, household status and secretion contact.
Interpretation and limitations
Eligibility is determined case by case using national criteria; broad unverified contact lists lead to over- and under-treatment.
03
Pregnancy, allergy and interaction review
Why
Select a safe agent without delaying prophylaxis.
Interpretation and limitations
Check fluoroquinolone restrictions, severe beta-lactam allergy, rifampicin interactions, contraception, anticoagulation, pregnancy and breastfeeding.
04
Index isolate typing and susceptibility
Why
Identify serogroup, resistance and vaccine implications.
Interpretation and limitations
Results can modify agent or trigger vaccination, but initial prophylaxis should not wait when health protection recommends immediate treatment.

04InterventionsLifestyle, treatment and escalation options.

01ASSESSDefine the exposed contactFirst stepA probable or confirmed meningococcal case creates concern among contacts.

1Notify health protection and provide secure index-case, onset, setting and exposure information for a formal contact assessment.
2Ask every potential contact about symptoms first and divert symptomatic people to emergency care without clinic delay.
3Distinguish household, intimate and direct secretion exposure from casual proximity and document the rationale for eligibility.
4Review pregnancy, allergy, renal function when relevant and major medicine interactions before selecting the approved regimen.

02TREATGive prompt carriage eradicationHealth protection confirms an asymptomatic person meets prophylaxis criteria.

1Give ciprofloxacin 500 mg orally once when the current health-protection recommendation and individual safety support it.
2Use ceftriaxone 250 mg intramuscularly once when pregnancy, resistance or another factor makes it preferable.
3Use rifampicin 600 mg twice daily for 2 days only after interaction, pregnancy and adherence review when selected.
4Ensure the index case receives carriage eradication if their therapeutic regimen did not provide it and do not repeat prophylaxis without advice.

03REVIEWAdd vaccination and safety-nettingSerogroup, setting or outbreak assessment identifies further prevention needs.

1Arrange serogroup-specific vaccination for contacts or wider groups when health protection identifies benefit.
2Explain that antibiotics reduce carriage but do not guarantee prevention and give explicit emergency symptoms and action.
3Document agent, dose, date, batch or administration details, vaccine and the health-protection reference for continuity.
4Report adverse events and any secondary compatible illness immediately and re-contact health protection rather than self-prescribing.

05Medicines and treatment safetyRegimens, contraindications and review points.

Rapidly eradicates meningococcal nasopharyngeal carriage and reduces secondary disease.

Ciprofloxacin meningococcal prophylaxis

Give ciprofloxacin 500 mg orally once to an eligible adult contact when susceptibility and safety permit.

Apply current MHRA fluoroquinolone restrictions, pregnancy and interaction review and use an alternative after a resistance alert.

Provides highly effective single-dose carriage eradication without rifampicin induction.

Ceftriaxone prophylaxis

Give ceftriaxone 250 mg intramuscularly once to an eligible adult when selected, including pregnancy-compatible use.

Check severe beta-lactam allergy and injection considerations and distinguish this prophylactic dose from meningitis treatment dosing.

Eradicates carriage when single-dose options are unsuitable.

Rifampicin prophylaxis

Give rifampicin 600 mg orally every 12 hours for 2 days to an eligible adult when health protection selects it.

Potently induces contraception, anticoagulants and many medicines, stains secretions orange, has liver toxicity and must not treat symptomatic disease.

06Targets, monitoring and follow-upResponse, safety and longer-term review.

Confirm every eligible contact receives the complete dose promptly and record reasons when prophylaxis is declined or changed.
Check vaccine recommendations and ensure appointments and subsequent doses are owned by a named service.
Provide written symptom safety-netting for fever, headache, rash, limb pain, confusion and rapid deterioration after prophylaxis.
Feed secondary cases, adverse events, resistance results and missed high-risk contacts back to health protection immediately.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

Carriage is the target

Prophylaxis is designed to clear nasopharyngeal meningococci, not to treat bloodstream or meningeal infection.

Exposure is specific

The decisive event is close household-like or direct secretion contact, not simply being in the same building.

Vaccine and antibiotic differ

Antibiotics remove current carriage, whereas vaccination protects against future disease from covered serogroups; some contacts need both.

Index cases may need clearance

Ceftriaxone usually clears carriage, while other therapeutic regimens may require an additional eradication dose before discharge.

08Common pitfallsFrequent interpretation and management errors.

01
Giving a single ciprofloxacin prophylaxis dose to a symptomatic contact instead of emergency treatment.
02
Offering antibiotics to every colleague, classmate or healthcare worker without exposure assessment.
03
Forgetting rifampicin interactions with hormonal contraception, anticoagulation and other essential medicines.
04
Assuming prophylaxis removes all risk and omitting vaccination assessment and symptom safety-netting.